Laboratories Griffon Pvt Ltd v. Ramesht Industry Pvt Ltd

In the pharmaceutical world, a brand name is more than a label, it is a promise of trust, consistency, and patient safety. When that name is copied, the damage goes far beyond lost sales; it strikes at the heart of credibility. The dispute between Laboratories Griffon Pvt. Ltd. and Ramesht Industry Pvt. Ltd. is a stark reminder that in healthcare branding, similarity is not a minor detail, it is the entire battleground.

Laboratories Griffon Pvt. Ltd., the plaintiff in this case, had built its identity around a family of pharmaceutical marks, GLIMET, GLIMET-1, and GLIMET-2, used for products aimed at treating diabetes. These marks were registered trademarks, giving the company formal recognition of their distinctiveness in the market. Ramesht Industry Pvt. Ltd., the defendant, entered the same therapeutic space using identical or confusingly similar marks for its own diabetes-related products. Believing that its registered rights were being eroded and that consumers were likely to be misled, Laboratories Griffon approached the court seeking relief for trademark infringement and passing off.

Laboratories Griffon argued that its marks, GLIMET, GLIMET-1, and GLIMET-2, were its registered intellectual property and had acquired a distinct identity in the pharmaceutical market, particularly among diabetes patients and prescribers. The use of identical marks by Ramesht Industry, they contended, was a clear case of infringement and passing off, designed to ride on the goodwill already established by the original brand. Ramesht Industry, on the other hand, positioned its case around the idea that differences in formulation or product composition should matter in determining whether confusion was likely. The core legal friction was simple but powerful: does the registration of a trademark, combined with identical use in the same class of goods, automatically create a prima facie case of infringement, regardless of whether the underlying formulations differ?

The Court sided with Laboratories Griffon. It found that a prima facie case of trademark infringement and passing off had been made out by the plaintiffs. The Court reasoned that the registration of a trademark serves as formal recognition of its inherent distinctiveness, and when identical marks are deployed for goods falling within the same class, the likelihood of confusion and deception is presumed. The fact that the formulations behind the marks may have differed was not enough to defeat the claim. Based on this reasoning, the Court granted an ad-interim injunction in favor of Laboratories Griffon, restraining Ramesht Industry from using the contested GLIMET marks during the pendency of the proceedings.

For founders and IP professionals in the pharmaceutical space, this case delivers a clear and urgent message: a registered trademark is not just a legal formality, it is a fortified boundary around your brand's identity. If you operate in a therapeutic category where patients and doctors rely on familiar names, even a closely similar mark can be treated as infringement. Before launching any product, conduct thorough trademark searches, respect the boundaries of existing registrations, and remember that in the same class of goods, identical branding will almost always be viewed by the courts as a shortcut to someone else's goodwill. Build your own distinct identity; do not borrow another company's.